Effects of leukemia inhibitory factor on 3T3-L1 adipocytes

Jessica C Hogan and Jacqueline M Stephens

Department of Biological Sciences, 202 Life Sciences Building, Louisiana State University, Baton Rouge, Louisiana 70803, USA

(Requests for offprints should be addressed to J M Stephens; Email: jsteph1@lsu.edu)

Abstract

Leukemia inhibitory factor (LIF) is a member of the gp130 cytokine family and signals through the receptor complex of gp130 and the LIF receptor (LIFR) to activate the JAK/STAT signaling cascade. Since LIF activates STATs 1 and 3 in adipocytes, we examined the effects of LIF on 3T3-L1 adipocytes. Our studies clearly demonstrate that LIF treatment had minimal effects on adipocyte differentiation as judged by marker gene expression, but did inhibit triacylglyceride (TAG) accumulation during adipogenesis. Acute treatment with LIF resulted in increased expression of suppressors of cytokine signaling-3 (SOCS3) and CCAAT/enhancer-binding protein-δ (C/EBPδ) mRNA in 3T3-L1 adipocytes. Moreover, the upregulation of C/EBPδ correlated with binding to three sites in the C/EBPδ promoter by LIF-activated protein complexes that contained STAT1 and not STAT3. Chronic treatment with LIF resulted in decreased protein levels of sterol regulatory element binding protein-1 (SREBP1) and fatty acid synthase (FAS), but had no effect on the expression of other adipocyte marker proteins or on TAG levels in mature 3T3-L1 adipocytes. LIF had a small effect on insulin-stimulated glucose uptake in 3T3-L1 adipocytes, but did not cause insulin resistance following chronic treatment. These findings indicate that LIF has similar and distinct effects in comparison with the effects of other gp130 cytokines on cultured fat cells. In summary, our results support a role for LIF in the regulation of proteins involved in lipid synthesis and in the modulation of signal transduction pathways in 3T3-L1 adipocytes.

Journal of Endocrinology (2005) 185, 485–496

Introduction

Leukemia inhibitory factor (LIF) is a member of the gp130 cytokine family, cytokines which are unrelated by sequence, but are structurally similar and share a common receptor, gp130 (Robinson et al. 1994, Kishimoto et al. 1995). LIF has pleiotropic actions which include maintaining totipotency of embryonic stem cells (Williams et al. 1988), enhancing survival of peripheral neurons (Murphy et al. 1991) and oligodendrocytes (Butzkeuen et al. 2002), and promoting bone formation (Dazai et al. 2000). LIF has also been demonstrated to have multiple effects on adipocytes and adipose tissue. Initially, LIF was characterized as an inducer of cachetic weight loss in mice engrafted with a melanoma cell line that overproduces LIF (Mori et al. 1989). Subsequently, LIF was found to inhibit lipoprotein lipase (LPL) expression and activity in 3T3-L1 and 3T3-F442A adipocytes, without affecting the rate of lipogenesis (Marshall et al. 1994). In addition, adipogenic effects of LIF have been indicated by enhanced activity of glycerol-phosphate dehydrogenase and accumulation of lipid in Ob1771 cells during adipogenesis (Aubert et al. 1999). However, other findings have shown that LIF prevents adipogenesis in bone marrow stromal cells (Gimble et al. 1994) and in 3T3-L1 cells (Ohsumi et al. 1994). Thus, it is likely that the effects of LIF on adipocytes vary with the developmental stage of the cells or tissue.

Cytokines in the gp130 family exhibit functional redundancy as they signal through shared receptor components (Kishimoto et al. 1995). Ciliary neurotropic factor (CNTF), oncostatin M, cardiotropin-1 (CT-1), and LIF bind the LIF receptor (LIFR), in addition to the common receptor, gp130 (Baumann et al. 1993, Wollert et al. 1996). Oligomerization of LIFR and gp130 activates the associated JAK kinase, which phosphorylates tyrosine moieties on the cytoplasmic tail of the receptor. The phosphorylated tyrosines serve as docking sites for signal transducers and activators of transcription (STATs) 1 and 3, which then become phosphorylated, dissociate and form dimers. The STAT dimers immediately translocate to the nucleus to regulate expression of target genes.

Recent work in our laboratory has examined the effects of two other gp130 cytokines, CNTF and CT-1, on adipocytes (Zvonc et al. 2003, 2004). CNTF increased expression and activation of insulin signaling molecules in 3T3-L1 adipocytes, but decreased expression of fatty acid synthase (FAS) and sterol regulatory element binding protein-1 (SREBP1). Like CNTF, CT-1 decreased expression of FAS protein but also decreased expression of insulin receptor substrate-1 (IRS-1) in 3T3-L1 adipocytes, indicating both overlapping and divergent effects of gp130 proteins.
certain cytokines on adipocytes. To further elucidate the role of gp130 cytokines on adipocytes, we have investigated the action of LIF on 3T3-L1 adipocytes. As previously observed with CT-1 and CNTF, LIF neither promoted nor attenuated adipogenesis, in contrast to previous findings for LIF (Gimble et al. 1994, Aubert et al. 1999). We have also shown that FAS and SREBP1 protein levels decreased after a chronic treatment with LIF. In addition, both suppressors of cytokine signaling-3 (SOCS3) and CCAAT/enhancer-binding protein-δ (C/EBPδ) mRNA were rapidly induced following treatment of 3T3-L1 adipocytes with LIF. We identified three STAT1 binding sites in the C/EBPδ promoter at positions −696 to −679, −780 to −763, and −1491 to −1475. Unlike other gp130 cytokines, LIF had no effect on basal or insulin-stimulated glucose uptake, or on the expression of the insulin responsive glucose transporter GLUT4. In summary, our results demonstrate novel and specific effects of LIF on 3T3-L1 adipocytes, suggesting a role for LIF as a regulator of lipid synthesis and an effector of signal transduction in fat cells.

Materials and Methods

Materials

Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), and leukemia inhibitory factor (LIF) were purchased from Invitrogen. Murine interferon-γ (IFNγ) was purchased from Boehringer Mannheim. Bovine serum and growth hormone (GH) were purchased from Sigma. Foxo1, STAT1, STAT3, and highly phospho-specific STAT5 (Tyr649) antibodies were purchased from Upstate Biotechnology. STAT3, highly phospho-specific STAT3 (Tyr705) antibodies were purchased from Santa Cruz (Santa Cruz, CA, USA); STAT1, STAT5A, peroxisome proliferator-activated receptor-γ (PPARγ), and SREBP1 antibodies were purchased from Santa Cruz (Santa Cruz, CA, USA); STAT3, highly phospho-specific STAT3 (Tyr705) antibody and FAS antibody were purchased from BD Transduction Laboratories (San Jose, CA, USA). LPL antibody and FAS antibody were purchased from BD Transduction Laboratories (San Jose, CA, USA). LPL antibody and FAS antibody were purchased from BD Transduction Laboratories (San Jose, CA, USA). LPL antibody and FAS antibody were purchased from BD Transduction Laboratories (San Jose, CA, USA). LPL antibody and FAS antibody were purchased from BD Transduction Laboratories (San Jose, CA, USA). LPL antibody and FAS antibody were purchased from BD Transduction Laboratories (San Jose, CA, USA).

Cell culture

Murine 3T3-L1 preadipocytes were plated and grown to 2 days post-confluence in DMEM containing 10% bovine serum. Medium was changed every 48 h. Cells were induced to differentiate by changing the medium to DMEM containing 10% FBS, 0.5 mM 3-isobutyl-methylxanthine, 1 μM dexamethasone, and 1.7 μM insulin (MDI). After 48 h, this medium was replaced with DMEM supplemented with 10% FBS, and the cells were maintained in this medium until utilized for experimentation.

Preparation of whole cell extracts

Cells monolayers were rinsed with PBS and then harvested in a non-denaturing buffer containing 10 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% Nonidet P-40, 1 μM phenylmethyl-sulfonyl fluoride, 1 μM pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10 μM leupeptin, and 2 mM sodium vanadate. Samples were extracted for 30 min on ice and centrifuged at 15 000 r.p.m. at 4°C for 15 min. Supernatants containing whole cell extracts were analyzed for protein content by BCA analysis (Pierce) according to the manufacturer’s instructions.

Gel electrophoresis and immunoblotting

Proteins were separated in 7.5% polyacrylamide (National Diagnostics, Atlanta, GA, USA) gels containing sodium dodecyl sulfate (SDS) according to the method of Laemmli (1970) and transferred to nitrocellulose (Bio-Rad) in 25 mM Tris, 192 mM glycine, and 20% methanol. Following transfer, the membrane was blocked in 4% milk overnight at 4°C. Results were visualized with horse-radish peroxidase (HRP)-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grave, PA, USA) and enhanced chemiluminescence (Pierce Biotechnology, Rockford, IL, USA).

Determination of 2-deoxyglucose

The assay of 2-[3H]deoxyglucose was performed as previously described (Stephens & Pekala 1991). Briefly, mature 3T3-L1 adipocytes were serum deprived for 4 h and then incubated in the presence or absence of insulin (44 nM) for 10 min. Glucose uptake was initiated by addition of 2-[3H]deoxyglucose at a concentration of 0.1 mM 2-deoxyglucose in 1 μCi 2-[3H]deoxyglucose in Krebs-Ringer-Hepes buffer and incubated for 3 min at room temperature. Glucose uptake is reported as [3H]radioactivity, corrected for nonspecific diffusion (5 μM cytochalasin B) and normalized to total protein content as determined by BCA analysis. Uptake measurements were performed in triplicate under conditions where hexose uptake was linear.

RNA analysis

Total RNA was isolated from cell monolayers with Trizol (Invitrogen) according to the manufacturer’s instructions.
with minor modifications. For Northern blot analysis, 15 μg total RNA were denatured in formamide and electrophoresed through a formaldehyde/agarose gel. The RNA was transferred to Zeta Probe-GT (Bio-Rad), cross-linked, hybridized, and washed as previously described (Stephens & Pekala 1992). Strippable probes were labeled by random priming using the Klenow fragment and [γ-32P]dATP using Strip-EZ DNA (Ambion, Austin, TX, USA) according to manufacturer’s instructions.

Electrophoretic mobility shift analysis (EMSA)

Double-stranded oligonucleotides were annealed by heating single-stranded 5’ and 3’ oligonucleotides in a boiling water bath and gradually cooling to room temperature. The 4 μg of double-stranded oligonucleotides were 5’-end labeled with 20 μCi [32P] (400–800 Ci/mmol) dCTP and with 1 μl each of 5 mM dATP, dTTP, and dGTP with Klenow fragment. The end-labeling reaction was incubated for 15 min at 30 °C and was stopped by adding 1 μl 0·5 M EDTA. End-labeled oligonucleotides were purified using a Microspin G-25 column, according to the manufacturer’s instructions (Amersham Biosciences). Specific activity of the oligonucleotides was determined by scintillation counting. Nuclear extracts were incubated with the end-labeled oligonucleotides (50 000 c.p.m./μl) for 30 min on ice. The samples were loaded into a pre-run (1 h, 100 V at 4 °C) 6% acrylamide/bisacrylamide TBE gel containing 90 mM Tris, 90 mM boric acid, and 2 mM EDTA, pH 8·0. For supershift analysis, nuclear extracts were incubated with a Triton X-100/methyl alcohol mixture (1:1 vol/vol), and were then assayed for trypsin activity of the oligonucleotides was determined by scintillation counting. Nuclear extracts were incubated with a Microspin G-25 column, according to the manufacturer’s instructions (Sigma). Triglyceride levels were normalized to protein content by BCA (Pierce). Each treatment condition was performed in triplicate and each sample was analyzed twice.

Statistical analysis

The statistical analyses of the data were performed using ANOVA and the post hoc Schefé F-test.

Results

To determine if LIF treatment could modulate adipogenesis, 3T3-L1 preadipocytes were induced to differentiate in the presence or absence of exogenously added LIF. The cells were exposed to LIF (0·5 nM) for the entire course of differentiation with a fresh bolus of LIF added at the time of induction and every 24 h after that. Whole cell extracts were harvested at the time points indicated in Fig. 1 and were analyzed by Western blotting. Adipogenesis was assessed by induction of PPARγ, C/EBPα, fatty acid transport protein-4 (FATP4), STAT5A, FAS and adiponectin proteins. Although LIF attenuated the induction of PPARγ, C/EBPα, and FAS at 48 h and/or 72 h, LIF did not affect the overall expression of these markers of adipogenesis at 120 h. The induction in STAT5A expression was unaffected by the presence of LIF. The induction of adiponectin was decreased at 96 h, but present at similar levels at 120 h. The expression of STAT3 does not change during adipogenesis (Stewart et al. 1999) and is shown as a loading control (Fig. 1). Phosphorylation of STAT3 was detected in preadipocytes following 15 min stimulation with LIF. A longer exposure of the film detected a low level of STAT3 phosphorylation through the course of differentiation.

Since LIF is a potent activator of STATs 1 and 3 in 3T3-L1 cells (Stephens et al. 1998) we examined the action of LIF on mature adipocytes. Whole cell extracts were collected from fully differentiated 3T3-L1 adipocytes that were treated with LIF for the various times indicated in Fig. 2. Although the phosphorylation of STATs 1 and 3 was detected at 15 and 45 min of stimulation, there were no changes in the level of PPARγ, Foxo1, SREBP1, FAS, or acetyl CoA carboxylase (ACC) proteins during the time course (Fig. 2). Therefore, we investigated the effect of a chronic LIF treatment on 3T3-L1 adipocytes. Fully differentiated adipocytes were stimulated with LIF for the times indicated in Fig. 3, with a fresh bolus of LIF added every 24 h. Chronic LIF treatment resulted in decreased protein levels of FAS and SREBP1 at 120 h, but the levels for Foxo1, PPARγ, LPL and ACC were unchanged. Efficacy of LIF treatment is shown by the phosphorylation of STAT3 during the time course, and positive controls for activation of STATs 1, 3 and 5 are shown with extracts from 3T3-L1 adipocytes stimulated for 15 min with IFNγ, LIF and GH respectively.

Since other gp130 cytokines have been reported to have effects on insulin signaling and glucose uptake, we investigated the ability of LIF to regulate glucose uptake in 3T3-L1 adipocytes. As shown in Fig. 4A, mature 3T3-L1 adipocytes were pretreated with LIF for 30 min, 48 h or 96 h. Adipocytes were stimulated with insulin for 15 min and assayed for uptake of 2-[3H]deoxyglucose. As shown in Fig. 4A, insulin treatment induced an approximately fourfold increase in glucose uptake for all time points (ANOVA F (7,16) = 123·37, P = 1·02E-12; Scheffé’s test).
We observed no significant effects of LIF on the levels of insulin-stimulated glucose uptake. Moreover, LIF had no effects on basal glucose uptake. We also examined the effects of LIF on glucose uptake over an acute time course of treatment, as shown in Fig. 4B. We observed an approximately fourfold increase in glucose uptake for all time points (ANOVA F (9,19)=59.72, \( P=4.93\times10^{-12} \); Scheffé’s test). Exposure to LIF for 1 or 4 h had no effect on insulin-stimulated glucose uptake; however, at 2 h, there was a consistently observed decrease in insulin-stimulated glucose uptake, but this was not statistically significant, as shown in Fig. 4B. We observed no significant effects of LIF on basal glucose uptake (Fig. 4B). Furthermore, there were no effects on the level of GLUT4 mRNA over a time course of 24 h (Fig. 5). We also examined the effects of a 2-h pretreatment with CT-1 on glucose uptake. Basal or insulin-stimulated levels of glucose uptake were not significantly different from control levels (Fig. 4B).

To examine the effects of LIF on the regulation of mRNA for several adipocyte genes, total RNA was collected from fully differentiated 3T3-L1 adipocytes following treatment with LIF for the times indicated in Fig. 5. Although no changes were detected for C/EBPα, C/EBPβ, or aP2, LIF induced a rapid and transient upregulation of mRNA for SOCS3 and C/EBPβ within one hour of stimulation. Furthermore, the upregulation of SOCS3 and C/EBPβ was independent of ERK/MAP kinase activity, as pretreatment with the MEK inhibitor, U0126, did not block the induction by LIF (data not shown). Induction of SOCS3 by gp130 cytokines has been demonstrated in adipocytes (Zvonic et al. 2004) and is well characterized in other cell types (Krebs & Hilton 2001).

The role of STAT3 in the upregulation of C/EBPβ has been investigated in other cell types, and evidence indicated that the −115 to −98 site in the C/EBPβ promoter was bound by STAT3 following stimulation with interleukin (IL)-6 (Yamada et al. 1997, Hutt et al. 2000). Hence, we examined the ability of LIF to induce binding to the −115 to −98 element of the C/EBPβ promoter. Electromobility shift assay was performed with nuclear extracts from 3T3-L1 adipocytes treated with LIF for 15 min. As shown in Fig. 6, no detectable binding to the −115 to −98 oligonucleotide was observed with LIF treatment, indicating that this site does not contribute to the regulation of C/EBPβ by LIF in 3T3-L1 adipocytes. Thus, we looked for other possible STAT binding sites in...
the C/EBPβ promoter and identified four sites at positions −616 to −599, −696 to −679, −780 to −763, and −1491 to −1475 that resembled the consensus STAT recognition sequence TTCNNNGAA (Table 1). Free (on Fig. 6) indicates the presence of the probe alone with no added protein extract to the sample. As shown in Fig. 6, LIF-induced nuclear protein complexes shifted the sites at −696 to −679, −780 to −763, and −1491 to −1475, but not the −616 to −599 oligonucleotide (data not shown). Cold competition analysis with excess unlabeled oligonucleotides revealed the specificity of these interactions (data not shown). Because LIF is a strong activator of STAT3 (see Figs 2 and 3), we hypothesized that the protein complex contained STAT3. However, supershift analysis using multiple STAT3 antibodies, along with antibodies against STAT1 and STAT5A clearly indicates that the protein complex induced by LIF primarily contains STAT1 (Fig. 7A, panels 1–3, lane 7). As shown in Fig. 7A, no supershift was detected with a STAT5A antibody (lane 8) or with STAT3 antibodies that recognize the carboxy terminus (lane 4), amino acids 1–175 (lane 5), or amino acids 688–722 (lane 6) of STAT3. We also examined the induction of binding by LIF-induced proteins to two oligonucleotides that are routinely used as positive controls for STAT3 binding, the −168 to −148 site from the rat α2-macroglobulin (α2M) promoter (Hattori et al. 1990) and the m67 oligonucleotide derived from the c-fos −345 to −323 promoter, which strongly binds cytokine-induced protein complexes (Wagner et al. 1990). As shown in Fig. 7A, LIF treatment induced binding to these oligonucleotides (panels 4 and 5, lane 3). Similar to our findings with the C/EBPβ promoter sites, only STAT1 antibody supershifted the protein complex induced by LIF for both the m67 and α2M oligonucleotides. To further investigate the activation of STAT3 binding by LIF, we used a longer m67 oligonucleotide for EMSA analysis (Fig. 7B). We detected binding by two protein complexes that were induced by LIF. The weak binding by the protein complex exhibiting slower mobility was blocked by antibodies for STAT3 (lanes 4 and 5). The more prominent protein complex exhibiting faster mobility was supershifted by STAT1.
agonist (lane 6). STAT5A antibody was included as a negative control. Thus, although LIF is a potent activator of STAT3, STAT1 appears to preferentially bind under these conditions in 3T3-L1 adipocytes. Furthermore, our supershift analysis suggests that STAT1 contributes to the LIF-induced modulation of C/EBPβ in adipocytes.

Since we observed a delay in the expression of several adipocyte marker proteins during adipogenesis in the presence of LIF, we examined the effect of LIF on the accumulation of triglycerides (TAG) during the differentiation of 3T3-L1 cells. 3T3-L1 preadipocytes were induced to differentiate in the presence or absence of LIF (0.5 nM). A fresh bolus of LIF was added every 24 h. Cells were harvested at the times indicated in Fig. 8A. As shown in Fig. 8A, in the absence of LIF treatment, triglyceride content increased during differentiation (ANOVA F (7,16) = 28.51, P = 0.88E-8; Scheffé’s test). Although the triglyceride content also increased in the LIF-treated cells during adipogenesis, the level of triglycerides in LIF-treated cells at 120 h was significantly lower than the level observed in the untreated adipocytes (Fig. 8A). We also examined the effect of LIF on triglyceride content in mature adipocytes. Mature 3T3-L1 adipocytes were stimulated with LIF for the various times indicated in Fig. 8B. As shown in Fig. 8B, LIF treatment did not diminish the level of triglyceride in 3T3-L1 adipocytes (ANOVA F (5,6) = 0.30, P = 0.89).

Discussion

Recent work from our laboratory has demonstrated that gp130 cytokines, CT-1 and CNTF, have overlapping and divergent effects on the expression and activation of proteins of lipid and glucose metabolism in adipocytes (Zvonic et al. 2003, 2004). The gp130 cytokines activate the JAK/STAT pathway via the gp130 and LIF receptors. Because LIF also signals through gp130 and LIFR, we hypothesized that LIF would regulate adipocyte proteins. Our studies with 3T3-L1 cells have shown that LIF activates STATs 1 and 3 in preadipocytes and mature adipocytes. Because LIFR is expressed more abundantly in preadipocytes (Zvonic et al. 2003), we predicted that LIF would regulate adipogenesis as was previously shown in 3T3-L1 cells (Ohsumi et al. 1994). However, we observed only modest effects of LIF on the in vitro differentiation of 3T3-L1 adipocytes. In another cell line, Ob1771, LIF promotes differentiation (Aubert et al. 1999). Thus, it is possible that this discrepancy is due to differences in commitment to the adipocyte lineage of these two cell lines.

Since adipocytes are responsive to LIF, we studied the effects of this cytokine on fully differentiated adipocytes. Acute treatment did not regulate the expression of several adipocyte proteins, but expression of SOCS3 and C/EBPβ mRNA was strongly and transiently stimulated by LIF. SOCS3 is a member of the SOCS protein family, which is characterized by the ability to negatively modulate cytokine signaling (Krbs & Hilton 2001). The induction of SOCS3 expression has been demonstrated by many cytokines, and direct regulation by STAT proteins has been described (Auernhammer et al. 1999). These data are consistent with recent findings from our laboratory that CNTF and CT-1 upregulate SOCS3 mRNA (Zvonic et al. 2004). Interestingly, there is recent evidence that SOCS3 is a regulator of insulin signaling and may cause insulin resistance in adipocytes through its effects on IRS protein expression (Shi et al. 2004). Although we did not observe any significant effects on insulin-stimulated glucose uptake by LIF, the upregulation of SOCS3 by gp130 cytokines is clearly a major component of JAK/STAT signaling in adipocytes.
C/EBPδ is a basic-leucine zipper transcription factor with a well-established role in adipogenesis (Darlington et al. 1998), although knock-out studies indicate that C/EBPδ alone is weakly adipogenic (Tanaka et al. 1997). The IL-6 upregulation of C/EBPδ in mammary epithelium (Hutt et al. 2000) and HepG2 cells (Yamada et al. 1997) has been shown to be mediated by the −115 to −98 region of the promoter, but our data indicated that this site was not sensitive to LIF regulation in adipocytes (Fig. 6). However, three other sites at positions −696 to −679, −780 to −763, and −1491 to −1475 were bound by LIF-activated protein complexes which contained STAT1 (Fig. 6). Interestingly, the protein complex did not contain STAT3, as we had predicted, since LIF is a more potent activator of STAT3 than of STAT1, as shown in Fig. 2. Moreover, we did not observe STAT3 binding to two oligonucleotides routinely used as positive controls for STAT3 binding, the −168 to −148 site of the rat α2M promoter (Hattori et al. 1990) and m67 (Wagner et al. 1990). Yet, our supershift analysis revealed that these oligonucleotides were shifted by protein complexes which contained STAT1. Only when we used a long form of the m67 oligonucleotide did we detect a faint band that represented a STAT3 binding site. Our

Figure 4 LIF does not affect insulin stimulation of glucose uptake. (A) Fully differentiated 3T3-L1 adipocytes were treated with LIF (0·5 nM) for the times indicated. Cells were treated every 24 h with a fresh bolus of LIF. Cells were serum deprived for 4 h and then stimulated with insulin (44 nM) for 15 min. Glucose uptake was initiated by addition of 2-[3H]deoxyglucose. Glucose uptake for each time point was measured in triplicate and is given as the mean ± S.D. (P<0.01; Scheffé’s test; ANOVA F (7,16)=123·37, $P=1·02E-12$). (B) Fully differentiated 3T3-L1 adipocytes were serum deprived for 4 h and were stimulated with LIF (0·5 nM) for the times indicated. Cells were then stimulated with insulin (44 nM) for 15 min. Glucose uptake was initiated by addition of 2-[3H]deoxyglucose. Glucose uptake for each time point was measured in triplicate and is given as the mean ± S.D. (P<0.01; Scheffé’s test; ANOVA F (9,19)=59·72, $P=4·93E-12$). This is a representative experiment independently performed two times. CTL, control untreated cells. In both (A) and (B) the only significant differences were between basal and insulin-stimulated conditions.
observations strongly suggest that STAT1 preferentially binds under these conditions in 3T3-L1 adipocytes. These results have led us to hypothesize that the three sites in the C/EBPβ promoter confer the LIF response and that binding by STAT1 may mediate the upregulation of C/EBPβ in adipocytes.

The consequences of increased expression of C/EBPβ in mature adipocytes are not known. It has been shown...
Table 1 Potential STAT binding sites in the C/EBPβ promoter

<table>
<thead>
<tr>
<th>Position</th>
<th>Sequence</th>
<th>LIF-responsive</th>
</tr>
</thead>
<tbody>
<tr>
<td>−115 to −98</td>
<td>TCG TTC CCA GCA GCA AC</td>
<td>No</td>
</tr>
<tr>
<td>−696 to −679</td>
<td>AAT TCC AGA ATA ATA TCC</td>
<td>Yes</td>
</tr>
<tr>
<td>−780 to −763</td>
<td>CTT TTC ACG AAT TTT GAA</td>
<td>Yes</td>
</tr>
<tr>
<td>−1491 to −1475</td>
<td>AT TTC TGG AAA AAT TGA A</td>
<td>Yes</td>
</tr>
<tr>
<td>−168 to −148 ω2,M</td>
<td>TCC TTC TGG GAA TC</td>
<td>Yes</td>
</tr>
<tr>
<td>m67</td>
<td>CGT TTC CCG TAA ATC CCT CCC</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>TTC NNN GAA</td>
<td></td>
</tr>
</tbody>
</table>

Figure 7 Binding of LIF-activated STAT1, not STAT3, to sites in the C/EBPβ promoter. Nuclear extracts were prepared from fully differentiated 3T3-L1 adipocytes that were untreated (−) or treated with LIF for 15 min. In the top panel of gels (A), the untreated (−) sample is present in lane 2 and the LIF treated samples are present in lanes 3–8. In the m67 gel (B), all the samples are LIF treated except the one labeled (−). For each sample, 10 μg protein were incubated with 50 000 c.p.m./ml of the 32P-labeled probe of the C/EBPβ promoter or of the STAT3 oligonucleotides for m67 or the −168 to −148 site of the rat ω2,M promoter. For supershift, samples were preincubated with the indicated antibodies (4 μg; STAT3 1 (Santa Cruz C-20), 2 (BD Transduction Laboratories), 3 (Upstate Biotechnology), STAT1 (Upstate Biotechnology), and STAT5 (Santa Cruz L-20). The protein–DNA complexes were resolved by electromobility shift assay. Free indicates the presence of the probe alone with no added protein extract to the sample. This is a representative experiment independently performed two times.

that tumor necrosis factor-α (Kurebayashi et al. 2001), dexamethasone (MacDougald et al. 1994), and insulin (MacDougald et al. 1995) also upregulate C/EBPβ in mature adipocytes in a rapid and transient manner. Interestingly, the lack of effect of LIF on C/EBPβ expression suggests that although C/EBPβ is regulated by C/EBPβ in differentiating adipocytes (Lane et al. 1999), it is not affected by C/EBPβ expression in mature adipocytes. In other cell types, C/EBPβ negatively regulates the expression of the α2 chain of type I collagen, a critical structural component of the extracellular matrix (Greenwel et al. 2000). C/EBPβ upregulates expression of IL-6 in astrocytes (Schwaninger et al. 2000), intestinal epithelial cells (Hungness et al. 2002), and osteoblasts (Ruddy et al. 2004); thus, IL-6, an adipokine associated with obesity (Bastard et al. 2000) may be a transcriptional target of C/EBPβ in adipocytes as well. Effects on C/EBPβ targets would likely be transient, since the induction of C/EBPβ is short-lived (MacDougald et al. 1994). These potential outcomes of increased C/EBPβ expression give insight into one means by which LIF exerts effects on adipocyte function.

We also examined the effect of a chronic administration of LIF in fully differentiated adipocytes. Both FAS and SREBP1 proteins exhibited decreased expression after 120 h of LIF stimulation. FAS is the enzyme catalyzing all of the steps in the synthesis of palmitate from acetyl CoA and malonyl, and the level of its expression is coupled to the rate of lipogenesis (Sul & Wang 1998). SREBP1 is a transcription factor known to modulate genes associated with fat and cholesterol metabolism (Horton et al. 2002), including FAS (Bennett et al. 1995). The decreased expression of SREBP1 and FAS may result in changes in lipid accumulation in adipocytes as a result of prolonged exposure to LIF. Indeed, LIF decreases TAG accumulation during adipogenesis, but has little effect on TAG levels in fully differentiated cells. However since the effects on SREBP and FAS require chronic treatment (5 days), it is highly likely that these effects are indirect.

In the light of recent studies demonstrating upregulation of GLUT4 expression by CTNF (Zvonic et al. 2003) and improved insulin-stimulated glucose uptake by CT-1 (Zvonic et al. 2004), we investigated the ability of LIF to
modulate glucose uptake in adipocytes. Our findings demonstrate that LIF does not substantially affect basal or insulin-stimulated glucose uptake, and does not modulate expression of GLUT4. Thus, LIF likely does not greatly affect glucose disposal in adipose tissue.

In summary, we have demonstrated that LIF activates the JAK/STAT pathway in 3T3-L1 preadipocytes and adipocytes. Although LIF had modest effects on adipogenesis of 3T3-L1 cells as judged by examining numerous fat markers, the presence of LIF during differentiation resulted in a significant decrease in TAG levels. We also demonstrated that LIF increased C/EBPβ expression after an acute exposure. We have identified three LIF-responsive sites in the C/EBPβ promoter that are distinct from the previously reported STAT3 binding site for IL-6 regulation in mammary epithelial cells (Hutt et al. 2000) and hepatocytes (Yamada et al. 1997). Moreover, these three newly identified and LIF-responsive sites bind STAT1, rather than STAT3. LIF, similar to CT-1 and CNTF, regulated proteins involved in lipid accumulation, SREBP1 and FAS, which may be indicative of a redundant role of gp130 cytokines in the modulation of adipocyte function. However, unlike these cytokines, LIF had no effect on basal or insulin-stimulated glucose uptake. These results were somewhat unexpected, given that all three cytokines signal through the same receptor components. Yet each cytokine activates a unique pattern of STATs in adipocytes. CNTF only activates STAT3 (Zvoníc et al. 2003), whereas LIF activates STATs 1 and 3, and CT-1 activates STATs 1, 3 and 5 (Zvoníc et al. 2004). Therefore, we predict that the variation in recruitment of these transcription factors mediates the

---

Figure 8  LIF diminishes the accumulation of triglycerides during adipogenesis. (A) 3T3-L1 cells were induced to differentiate in the presence or absence of LIF (0.5 nM). Cells were treated every 24 h with a fresh bolus of LIF. Cells were harvested in 2 M NaCl, 2 mM EDTA, 50 mM sodium phosphate, pH 7-4. Cell lysates were mixed in an equal volume of tert-butyl alcohol and 1 volume of a 1:1 mixture of Triton X-100 and methyl alcohol. Triglyceride content was measured according to package instructions (Sigma). The triglyceride level for each time point was measured in triplicate, normalized to protein concentration (mg/mg) and is given as the mean ± s.d. Asterisk indicates statistically significant difference compared with all time points (*P < 0.01; Scheffé’s test; ANOVA F (7,16)=28.51, P=6.88E-8). (B) Mature 3T3-L1 adipocytes were stimulated with LIF (0.5 nM) for the times indicated and were treated every 24 h with a fresh bolus of LIF. Triglyceride content was determined as described above (ANOVA F (5,6)=0.30, P=0.89). This is a representative experiment independently performed two times.
nonredundant downstream effects of gp130 cytokines in 3T3-L1 adipocytes. Furthermore, crosstalk with other signaling pathways may contribute to the divergent effects of gp130 cytokines. Current studies are underway to investigate the crosstalk among gp130 cytokines in adipocytes.

Acknowledgements

We would like to thank James E Baugh Jr for technical assistance with this project.

Funding

This work was supported by grant R01DK52968–02 from the National Institutes of Health to J M S. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References


MacDougald OA, Cornelius P, Lin FT, Chen SS & Lane MD 1994 Glucocorticoids reciprocally regulate expression of the C/EBA-enhancer-binding protein α and δ genes in 3T3-L1 adipocytes and white adipose tissue. *Journal of Biological Chemistry* 269 19041–19047.


www.endocrinology-journals.org


Stewart WC, Morrison RF, Young SL & Stephens JM 1999 Regulation of signal transducers and activators of transcription (STATs) by effectors of adipogenesis: coordinate regulation of STATs 1, 5A and 5B with peroxisome proliferator-activated receptor-γ and C/AAAT enhancer binding protein-α. Biochimica et Biophysica Acta **1452** 188–196.


Received in final form 25 February 2005
Accepted 4 March 2005
Made available online as an Accepted Preprint 9 March 2005